<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169624</url>
  </required_header>
  <id_info>
    <org_study_id>2004.346</org_study_id>
    <nct_id>NCT00169624</nct_id>
  </id_info>
  <brief_title>Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin</brief_title>
  <official_title>The DIAMET Study: Peripheral and Coronary Endothelial Dysfunction in Type 2diabetic Patients- Evaluation of Reversibility Following 3 Months of Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      Peripheral and coronary endothelial dysfunction in type 2 diabetic patients may be influenced
      by therapeutics. Using Radial flow monitoring and myocardial perfusion magnetic resonance
      imaging, we designed a controlled randomized double blind study to test the hypothesis that
      endothelial dysfunction will be reversed following 3 months of Metformin administration vs
      gliclazide. 30 patients will be included.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow dependent and independent Brachial artery vasoreactivity assessed using Doppler technology at 3 month vs baseline</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion improvement following improved vasoreactivity assessed using myocardial perfusion imaging at 3 month vs baseline</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Coronary and Peripheral Endothelial Dysfunction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18-70 years old, type 2 diabetes, non significant coronary atherosclerosis on inclusion
        coronary angiogram (ie no coronary stenosis &gt; 70%), HbA1c&lt;9%

        Exclusion Criteria:

        significant coronary stenosis (&gt;70%), lack of informed consent, unstable hypertension,
        renal failure, contra-indication to metformin or gliclazide, pregnancy, atrial
        fibrillation, contraindication to MRI, or to adenosine, brachial artery calcifications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent SEBBAG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laurent SEBBAG</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>October 4, 2007</last_update_submitted>
  <last_update_submitted_qc>October 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2007</last_update_posted>
  <keyword>Diabetes,</keyword>
  <keyword>coronary endothelial dysfunction,</keyword>
  <keyword>metformin,</keyword>
  <keyword>glyclazide,</keyword>
  <keyword>MRI.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

